EMEA-002431-PIP01-18

Key facts

Invented name
Alecensa
Active substance
Alectinib
Therapeutic area
Oncology
Decision number
P/0359/2018
PIP number
EMEA-002431-PIP01-18
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of non-small cell lung carcinoma (NSCLC)
Route(s) of administration
Oral use
Contact for public enquiries
Roche Registration GmbH

Tel.  +41 616879411
E-mail: info.paediatrics@roche.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating